Filtered By:
Drug: Donepezil

This page shows you your search results in order of date.

Order by Relevance | Date

Total 27 results found since Jan 2013.

Total saponins from Trillium tschonoskii Maxim promote neurological recovery in model rats with post-stroke cognitive impairment
Total saponins from Trillium tschonoskii Maxim (TSTT), a bioactive component of local natural herbs in the Enshi area, China, have been demonstrated to have functions of restoring cognitive capacity and promoting axonal regeneration post-stroke, but the mechanism of this process remains unclear. The hippocampus is a critical tissue for controlling learning and memory capacity, and the sonic hedgehog (Shh) signaling pathway plays a major role in the patterning and synaptic plasticity of hippocampal neural circuits. Therefore, we aimed to investigate whether TSTT could restore learning and cognitive functions by modulating t...
Source: Frontiers in Pharmacology - September 7, 2023 Category: Drugs & Pharmacology Source Type: research

The efficacy and safety of post-stroke cognitive impairment therapies: an umbrella review
Conclusion: Our study demonstrated that ACEI inhibitors (Donepezil) and NMDA antagonists (Memantine), EGB761, and acupuncture are the ADL and BI, MoCA, and neurological function deficit medication/therapy, respectively, for patients with PSCI.Clinical Trial Registration:https://inplasy.com/inplasy-2022-11-0139/; Identifier: INPLASY2022110139.
Source: Frontiers in Pharmacology - August 24, 2023 Category: Drugs & Pharmacology Source Type: research

FDA Approves Lecanemab, a New Alzheimer ’s Drug
On Jan. 6, the U.S. Food and Drug Administration (FDA) approved a new drug to treat Alzheimer’s disease in its early stages. Lecanemab, which will be available under the name Leqembi, can slow the cognitive decline associated with Alzheimer’s disease by 27%, according to data submitted to the FDA by the drug’s developers, Eisai and Biogen. It’s only the second medication to show any improvement in neurodegeneration, a key criterion in the FDA’s consideration for approval. “For a long time, this is what we have been looking for,” says Dr. Sam Gandy, professor of neurology and psychi...
Source: TIME: Health - January 6, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Drugs healthscienceclimate Source Type: news

Donepezil alone and combined with intensive language-action therapy on depression and apathy in chronic post-stroke aphasia: A feasibility study
Brain Lang. 2022 Dec 7;236:105205. doi: 10.1016/j.bandl.2022.105205. Online ahead of print.NO ABSTRACTPMID:36495749 | DOI:10.1016/j.bandl.2022.105205
Source: Brain and Language - December 10, 2022 Category: Neurology Authors: Marcelo L Berthier Lisa Edelkraut Francisco J L ópez-González Diana L ópez-Barroso Bettina Mohr Friedemann Pulverm üller Sergio E Starkstein Ricardo E Jorge Mar ía José Torres-Prioris Guadalupe D ávila Source Type: research

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis
CONCLUSIONS: We found moderate- to high-certainty evidence that donepezil 5 mg, donepezil 10 mg, and galantamine have a slight beneficial effect on cognition in people with VCI, although the size of the change is unlikely to be clinically important. Donepezil 10 mg and galantamine 16 to 24 mg are probably associated with more adverse events than placebo. The evidence for rivastigmine was less certain. The data suggest that donepezil 10 mg has the greatest effect on cognition, but at the cost of adverse effects. The effect is modest, but in the absence of any other treatments, people living with VCI may still wish to consid...
Source: Cochrane Database of Systematic Reviews - March 11, 2021 Category: General Medicine Authors: Ceri E Battle Azmil H Abdul-Rahim Susan D Shenkin Jonathan Hewitt Terry J Quinn Source Type: research

Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) – Still to be Considered in the Presence of Vascular Risk Factors
We report a 46-year-old male with a 9 and 3-month history of progressive unilateral lower limb weakness and dysarthria, respectively. He had a history of diabetes mellitus but no hypertension, hyperlipidemia, or smoking history. Both parents had a stroke at the age of 65 years. Neurological examination was significant for moderate dysarthria and reduced right upper limb dexterity. Magnetic resonance imaging (MRI) of the brain revealed extensive white matter disease, lacunar infarcts, and a few microhemorrhages. Electron microscopy of his skin biopsy showed electron-dense deposits of extracellular osmiophilic granular mater...
Source: Case Reports in Neurology - December 14, 2020 Category: Neurology Source Type: research

Donepezil in the treatment of ischemic stroke: Review and future perspective
Publication date: Available online 12 October 2020Source: Life SciencesAuthor(s): Arnavaz Hajizadeh Barfejani, Mahbod Jafarvand, Seyed Mohammad Seyedsaadat, Roozbeh Tarighati Rasekhi
Source: Life Sciences - October 13, 2020 Category: Biology Source Type: research

Donepezil down-regulates propionylation, 2-hydroxyisobutyrylation, butyrylation, succinylation, and crotonylation in the brain of bilateral common carotid artery occlusion-induced vascular dementia rats.
In this study, we evaluated the effects of donepezil on VaD, and investigated the underlying molecular mechanisms of action. VaD was established by ligation of the bilateral common carotid artery occlusion (BCCAO). Executive function was tested by the Morris Water Maze (MWM) test and the attentional set shifting task (ASST). Our results showed that donepezil improved executive dysfunction and cognitive flexibility in BCCAO rats. In addition, we showed that donepezil treatment decreased the level of Aβ1-42 in BCCAO rats by enzyme-linked immunosorbent assay. Posttranslational modifications (PTMs) are known to be critical me...
Source: Clinical and Experimental Pharmacology and Physiology - May 17, 2020 Category: Drugs & Pharmacology Authors: Wang H, Lu J, Gao WC, Ma X, Li N, Ding Z, Wu C, Zhu M, Qiao G, Xiao C, Zhang C, Chen C, Weng Z, Yang W, Zheng CB Tags: Clin Exp Pharmacol Physiol Source Type: research

Donepezil improves gait performance in patients with an acute cerebral infarction: a prospective observational cohort study.
CONCLUSION: Admission NIHSS score, age and multiple sites infarction were independent risk factors of WGS score. Donepezil could improve gait performance in patients with an acute cerebral infarction. PMID: 32282302 [PubMed - as supplied by publisher]
Source: Current Neurovascular Research - April 12, 2020 Category: Neurology Authors: Lin YY, Guo SJ, Quan H, Zhao YX, Huang DY Tags: Curr Neurovasc Res Source Type: research

Donepezil promotes neurogenesis via Src signaling pathway in a rat model of chronic cerebral hypoperfusion.
In this study, we investigated whether donepezil could promote SVZ neurogenesis in chronic cerebral hypoperfusion (CCH) injury via Src signaling pathway. In the bilateral carotid artery occlusion (2VO) rat model, we observed more nestin/5-bromo-2'-deoxyuridine (BrdU)-positive cells and doublecortin (DCX)/BrdU-positive cells in the SVZ than that in the sham group. Further, donepezil obviously improved neurologic function after 2VO, induced the greater number of SVZ proliferative NSCs and neuroblasts, and elevated levels of Src, p-FGFR1, p-EGFR, p-Akt and p-Raf in ipsilateral SVZ. Lastly, Src inhibitor KX-01 abolished the be...
Source: Brain Research - March 13, 2020 Category: Neurology Authors: Man J, Cui K, Fu X, Zhang D, Lu Z, Gao Y, Yu L, Li N, Wang J Tags: Brain Res Source Type: research

The efficacy and safety of pharmacological treatments for post-stroke aphasia.
Conclusions Current evidence suggests that drugs can improve the prognosis of post-stroke aphasia, such as donepezil, memantine. Donepezil has a significant effect in improving the ability of auditory comprehension, naming, repetition and oral expression. Memantine has a significant effect in improving the ability of naming, spontaneous speech and repetition. Bromocriptine showed no significant improvement in the treatment of aphasia after stroke. The trial for galantamine, amphetamine and levodopa in the treatment of aphasia after stroke is limited and inconclusive. PMID: 29984673 [PubMed - as supplied by publisher]
Source: CNS and Neurological Disorders Drug Targets - July 6, 2018 Category: Drugs & Pharmacology Authors: Zhang X, Shu B, Zhang D, Huang L, Fu Q, Du G Tags: CNS Neurol Disord Drug Targets Source Type: research

Acute aortic occlusion in a patient without risk factors
A 94-year-old female with a history of ischemic stroke, mild right hemiparesis, vascular dementia, breast cancer with right mastectomy, colon cancer resulting in colectomy, hyperlipidemia, and hypertension presented to the emergency department (ED) with bilateral leg pain. Patient had no smoking history, and her medications included Donepezil, Aspirin, Citalopram, Losartan, and Pantoprazole.
Source: The American Journal of Emergency Medicine - March 28, 2018 Category: Emergency Medicine Authors: Trina Stoneham, Erin L. Simon Source Type: research

Pharmacotherapy for Vascular Cognitive Impairment
AbstractVascular cognitive impairment (VCI) is the second most common type of dementia after Alzheimer ’s disease (AD). Stroke and cardiovascular risk factors have been linked to both AD and VCI and potentially can affect cognitive function in mid and later life. Various pharmacological agents, including donepezil, galantamine, and memantine, approved for the treatment of AD have shown modest cogni tive benefits in patients with vascular dementia (VaD). However, their functional and global benefits have been inconsistent. Donepezil has shown some cognitive benefit in patients with VaD only, and galantamine has shown some...
Source: CNS Drugs - August 7, 2017 Category: Neurology Source Type: research